4.8 Review

Aerosol drug delivery: developments in device design and clinical use

期刊

LANCET
卷 377, 期 9770, 页码 1032-1045

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(10)60926-9

关键词

-

资金

  1. Pfizer
  2. GlaxoSmithKline
  3. AstraZeneca
  4. Cogentus Pharmaceuticals
  5. Novartis Imaging
  6. Boehringer Ingelheim
  7. Bayer
  8. Novartis
  9. Sepracor and Trudell Medical International

向作者/读者索取更多资源

Aerosolised drugs are prescribed for use in a range of inhaler devices and systems. Delivering drugs by inhalation requires a formulation that can be successfully aerosolised and a delivery system that produces a useful aerosol of the drug; the particles or droplets need to be of sufficient size and mass to be carried to the distal lung or deposited on proximal airways to give rise to a therapeutic effect. Patients and caregivers must use and maintain these aerosol drug delivery devices correctly. In recent years, several technical innovations have led to aerosol drug delivery devices with efficient drug delivery and with novel features that take into account factors such as dose tracking, portability, materials of manufacture, breath actuation, the interface with the patient, combination therapies, and systemic delivery. These changes have improved performance in all four categories of devices: metered dose inhalers, spacers and holding chambers, dry powder inhalers, and nebulisers. Additionally, several therapies usually given by injection are now prescribed as aerosols for use in a range of drug delivery devices. In this Review, we discuss recent developments in the design and clinical use of aerosol devices over the past 10-15 years with an emphasis on the treatment of respiratory disorders.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据